1 / 40

A new look at T cell cancers “A Case Study of Translational Research”

A new look at T cell cancers “A Case Study of Translational Research”. William Cruikshank, PhD. Pulmonary Center. CREST Seminar Series 9/8/09. T cells B cells Monocyte/macrophage Dendritic cells Eosinophils Mast cells Fibroblasts Epithelial cells Glial cells Islet cells.

phyre
Télécharger la présentation

A new look at T cell cancers “A Case Study of Translational Research”

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A new look at T cell cancers“A Case Study of Translational Research” William Cruikshank, PhD Pulmonary Center CREST Seminar Series 9/8/09

  2. T cells B cells Monocyte/macrophage Dendritic cells Eosinophils Mast cells Fibroblasts Epithelial cells Glial cells Islet cells Binds to CD4 Induces migration Regulates T cell activation Maturation of DC Autoimmune diseases Allergic diseases Pre-eclampsia Surgical adhesion formation IL-16 Cells of Origin Bioactivity Associated pathology

  3. Interleukin-16 Pro-IL-16mature IL-16 Secreted by an unknown mechanism What happens to pro-IL-16? Is there an associated function?

  4. Nuclear and cytoplasmic distribution of IL-16 in primary T cells

  5. Pro-IL-16 expression in T cell lines

  6. The NLS of pro-IL-16 regulates the translocation of the IL-16 prodomain Zhang, Y. et al. J. Biol. Chem. 2001;276:1299-1303

  7. Mutation of the NLS significantly reduced nuclear targeting activity of the N-terminal prodomain of IL-16 Zhang, Y. et al. J. Biol. Chem. 2001;276:1299-1303

  8. Cell Cycle Analysis of Jurkat T cells Transfected with Wild Type or NLSM pro-IL-16 Propidium iodide labeling

  9. Simplified T Cell Cycle Regulation

  10. Nuclear presence of pro-IL-16 affects p27kip1 protein expression Dox IL-16

  11. Effect of nuclear pro-IL-16 on p27kip1 transcription

  12. Degradation of p27Kip1 by the F box SCFSkp2 ubiquitin E3 ligase complex

  13. Pro-IL-16 regulates Skp2 protein expression Dox IL-16

  14. Pro-IL-16 regulates Skp2 transcription

  15. Relationship of nuclear pro-IL-16 to lymphocyte cell cycle progression IL-16 (pro-IL-16) Skp2 p27Kip1 Resting state IL-16 (pro-IL-16) Skp2 p27Kip1 Proliferation

  16. Relationship of nuclear pro-IL-16 to lymphocyte cell cycle progression IL-16 (pro-IL-16) Skp2 p27Kip1 Resting state IL-16 (pro-IL-16) Skp2 p27Kip1 Proliferation

  17. GABPb, HDAC3 and HSC70 bind to pro-IL-16 (D) ChIP analysis using primers For GABPa binding region

  18. Nuclear membrane ? PDZ 1 PDZ 2 PDZ 3 Resting HDAC-3 HSC70 GABPb Deacetylation GABPa Skp2 Skp2 promoter Cell Cycle Arrest HDAC-3 Activated HSC70 GABPb GABPa Skp2 Skp2 promoter Cell Cycle Progression Scaffold function of Pro-IL-16 p27kip1 p27kip1

  19. So how do we get to T cell cancers?

  20. Sezary Syndrome • Cutaneous T cell lymphoma • Mycosis Fungoides lymphoma form and SS is the leukemic form • Rare disease (0.3/100,000) • Prognosis not good for later stage disease 2.5-5 yrs

  21. Patient Anti-C-term Anti-N-term DAPI Overlay Normal Control 1 3 5 7 8 10 Isotype Confocal images of intracellular IL-16 in T cells from Sezary patients

  22. Patients Normal Normal T-ALL 1 2 3 4 5 6 7 8 9 10 11 Pro-IL-16 Tubulin Actin Pro-IL-16/tubulin (densitometry) Patients Nuclear expression of Pro-IL-16 in T cells from Sezary patients

  23. Patients Normal Normal T-ALL 11 10 9 8 7 6 5 4 3 2 1 Subject p27KIP1 Skp2 Actin Expression of p27kip1 and Skp2 in Normal, T-ALL and Sezary Patients

  24. N PDZ1 PDZ2 PDZ3 SH3 bindng site N Patient 1 2 3 4 5 6 7 8 9 10 11 cDNA sequence analysis of Pro-IL-16 from Sezary patients GABPb HSC70

  25. B A HSC70 siRNA Control siRNA Control siRNA HSC70 siRNA Empty vector Nuclear stain Nuclear stain Untreated Merge Merge Pro-IL-16 Pro-IL-16 Dependence of HSC70 for Pro-IL-16 nuclear translocation

  26. 25,000 * * 20,000 15,000 Incorporated cpm 10,000 5,000 0 +pro-IL-16 Jurkat control +pro-IL-16+HSC70siRNA +pro-IL-16+control siRNA p27Kip1/Skp2 (densitometry) Thymidine Incorporation Cell Counts Cell Counts (x 105 cells) * * * * * * * * * * Days

  27. Sezary patients T-ALL 1 3 4 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 10 7 9 11 5 6 8 1 2 1 2 1 2 1 2 1 2 1 2 1 2 Relative Density Patients Normal Normal 1= total HSC70 2= HSC70 following i.p. for pro-IL-16

  28. Bioactive IL-16, ligand for CD4 PROINTERLEUKIN-16 Extracellular space aggregation Caspase 3 Cytoplasm Pro-IL-16 protein Cytoplasmic Pro-IL-16 IL-16 monomers CcN motif Cytoplasm Pro-IL-16 mRNA Nuclear Pro-IL-16 Nucleus Skp2 Constitutive p27Kip1 IL-16 gene G1 S G0 G2 M Cell cycle HSC70

  29. Bioactive IL-16, ligand for CD4 PROINTERLEUKIN-16 Extracellular space aggregation Caspase 3 Cytoplasm Pro-IL-16 protein Cytoplasmic Pro-IL-16 IL-16 monomers CcN motif Cytoplasm Pro-IL-16 mRNA Nuclear Pro-IL-16 Nucleus Skp2 Constitutive p27Kip1 IL-16 gene G1 S G0 G2 M Cell cycle Sezary mutation HSC70

  30. Bioactive IL-16, ligand for CD4 PROINTERLEUKIN-16 Extracellular space aggregation Caspase 3 Cytoplasm Pro-IL-16 protein Cytoplasmic Pro-IL-16 IL-16 monomers CcN motif Cytoplasm Pro-IL-16 mRNA Nuclear Pro-IL-16 Nucleus Skp2 Constitutive p27Kip1 IL-16 gene G1 S G0 G2 M Cell cycle HSC70

  31. Bioactive IL-16, ligand for CD4 PROINTERLEUKIN-16 Extracellular space HSC70 aggregation Caspase 3 Cytoplasm Pro-IL-16 protein Cytoplasmic Pro-IL-16 IL-16 monomers CcN motif Cytoplasm Pro-IL-16 mRNA Nuclear Pro-IL-16 Nucleus Skp2 Constitutive p27Kip1 IL-16 gene G1 S G0 G2 M Cell cycle

  32. Bioactive IL-16, ligand for CD4 PROINTERLEUKIN-16 Extracellular space HSC70 aggregation Caspase 3 Cytoplasm Pro-IL-16 protein Cytoplasmic Pro-IL-16 IL-16 monomers CcN motif Cytoplasm Pro-IL-16 mRNA Nuclear Pro-IL-16 Nucleus Skp2 Constitutive p27Kip1 IL-16 gene G1 S G0 G2 M Cell cycle

  33. Bioactive IL-16, ligand for CD4 PROINTERLEUKIN-16 Extracellular space HSC70 aggregation Caspase 3 Cytoplasm Pro-IL-16 protein Cytoplasmic Pro-IL-16 IL-16 monomers CcN motif Cytoplasm Pro-IL-16 mRNA Nuclear Pro-IL-16 Nucleus Skp2 Constitutive p27Kip1 IL-16 gene G1 S Cell cycle progression G0 G2 M Cell cycle

  34. Can a system for delivering Pro-IL-16 into Sezary T cells be used to effectively translate what we know into a therapeutic approach?

  35. Growth of primary T cells infected with murine stem cell virus expressing Pro-IL-16

  36. Effect of Pro-IL-16 expression on p27Kip1 levels in primary T cells

  37. Remaining Questions • What initiates the resultant mutation in Pro-IL-16 sequence? • Can loss of nuclear Pro-IL-16 be used as a predictor of disease progression? • Can an appropriate and effective delivery system be identified? • What is the specificity of the Pro-IL-16 mutation to Sezary Syndrome? (T-ALL not involved, Immunoblastic lymphadenopathy (ILD) IL-16 expression increased) • Does Pro-IL-16 regulate B cell proliferation?

  38. Acknowledgements Boston University BWH/DFCI Pulmonary Yujun Zhang David Jones Hisato Yamasaki Tom Kupper Chaungping Si Xiaoyi Jin Fred Little Arizona Medical Center Dan Green Clara Curiel Skin Oncology Program Marie-France Demeirre Adam Learner NIH Funding: NCI-CA122737 SP50CA093683

More Related